Lisata Therapeutics
LSTA
44 hedge funds and large institutions have $3.55M invested in Lisata Therapeutics in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 16 reducing their positions, and 9 closing their positions.
6% less funds holding
Funds holding: 47 → 44 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
42% less capital invested
Capital invested by funds: $6.13M → $3.55M (-$2.58M)
75% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$109K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$42.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$33.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$20.1K |
| 5 |
CI
Cowen Inc
New York
|
+$14.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$353K |
| 2 |
Millennium Management
New York
|
-$214K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$46K |
| 4 |
D.E. Shaw & Co
New York
|
-$45.3K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$34K |
LSTA Hedge Fund Activity: Q1 2016 in Review
44 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q1 2016, worth a combined $3.55M — down 42% from $6.13M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of LSTA and 6 opened new positions — a net loss of 3 holders — while 16 trimmed existing stakes and 4 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $109K. The largest seller was Great Point Partners, cutting an estimated $353K.
- 44 institutional investors held Lisata Therapeutics (LSTA) as of Q1 2016, down from 47 in Q4 2015.
- Funds reported $3.55M of Lisata Therapeutics stock for Q1 2016, down 42% quarter-over-quarter.
- 6 funds opened new Lisata Therapeutics positions in Q1 2016 and 9 closed out, a net change of -3 holders.
- The largest Lisata Therapeutics buyer in Q1 2016 was Jacobs Levy Equity Management, an estimated $109K added.
- The largest Lisata Therapeutics seller in Q1 2016 was Great Point Partners, an estimated $353K sold.
Based on aggregated 13F filings for Q1 2016.